Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Cord SunderkötterDirk Schneider

Abstract

Topical application of the calcineurin inhibitors pimecrolimus and tacrolimus is a current major advance in the therapy of atopic dermatitis. The aims of this post-marketing surveillance were: a) to acquire data on the efficacy and tolerability of pimecrolimus ointment (Elidel) on a very large cohort of patients from outpatient clinics, and b) to assess changes in their quality of life, a parameter not often considered in previous studies. Included were 5,665 patients with atopic dermatitis. During the observation period, data on efficacy and tolerability were obtained at the beginning of the study, 3 to 10 days after initiation of therapy and after 4 to 6 weeks. Evaluation of symptoms as well as assessment of efficacy and tolerability were based on linear scales and on the percentage of the body surface area (% BSA) involved. Quality of life was assessed by the German version of the "Dermatology Life Quality Index (DLQI)" or the "Children's Dermatology Life Quality Index (CDLQI)". In this largest post-marketing surveillance hitherto performed in Germany, the efficacy of pimecrolimus was judged as "good" by 79.3 % of physicians and by 76.5 % of patients. Tolerability was assessed as "good" by 87.2 % of physicians and by 83.1 % ...Continue Reading

References

Jun 1, 1995·The British Journal of Dermatology·M S Lewis-Jones, A Y Finlay
May 1, 1994·Clinical and Experimental Dermatology·A Y Finlay, G K Khan
Jan 1, 1994·Journal of the American Academy of Dermatology·J KayA G Jaron
Feb 1, 1997·Archives of Disease in Childhood·J C SuT M Nolan
Feb 1, 1997·The British Journal of Dermatology·M MorganR J Hay
May 20, 1999·The Australasian Journal of Dermatology·A Mar, R Marks
Dec 21, 2000·Clinical and Experimental Dermatology·H C Williams
May 16, 2002·International Journal of Dermatology·Gwendoline KiebertDavid Fivenson
Jul 3, 2002·Pediatrics·Ulrich WahnUNKNOWN Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group
Aug 10, 2002·The Journal of Allergy and Clinical Immunology·Alexander KappUNKNOWN Flare Reduction in Eczema with Elidel (infants) multicenter investigator study group
Oct 26, 2002·Dermatology : International Journal for Clinical and Investigative Dermatology·Michael MeurerUNKNOWN CASM-DE-01 study group
May 14, 2003·The Journal of Allergy and Clinical Immunology·Lawrence F Eichenfield, Lisa Beck
Jun 5, 2004·Dermatology : International Journal for Clinical and Investigative Dermatology·Michael MeurerUNKNOWN CASM-DE-01 Study Group
Nov 13, 2004·The Journal of Allergy and Clinical Immunology·Roland KaufmannUNKNOWN CASM981CDE04-Study Group
Nov 19, 2004·The British Journal of Dermatology·A AlomarUNKNOWN European Working Group on Atopic Dermatitis
Nov 25, 2004·Experimental Dermatology·M GrassbergerT A Luger

❮ Previous
Next ❯

Citations

Oct 4, 2007·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Thomas A LugerMatthias Bräutigam
Nov 14, 2008·Expert Opinion on Pharmacotherapy·Jan EhrchenMartin Steinhoff
Oct 6, 2006·Expert Opinion on Pharmacotherapy·Uwe WollinaMohamed Badawy Abdel-Naser
May 12, 2007·American Journal of Clinical Dermatology·Uwe Wollina
Nov 3, 2009·Paediatric Drugs·Lily P H Yang, Monique P Curran
Jun 1, 2010·American Journal of Clinical Dermatology·Lily P H Yang, Monique P Curran
Jun 6, 2009·American Journal of Clinical Dermatology·John R IngramAndrew Y Finlay
Apr 10, 2021·Journal of the European Academy of Dermatology and Venereology : JEADV·T LugerT Bieber

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.